COVID, Volume 2, Issue 11 (November 2022) – 8 articles

The worldwide coronavirus pandemic has been one of the most significant health crisis threats in recent years. COVID-19 has not been the only cause of mortality in this pandemic. A dangerous but frequent complication of viral infections is secondary superinfection or superimposed bacterial infection. Despite lacking data on the prevalence, microbiology, and outcomes of co-infection and superinfection, limited publications have reported the high incidence of severe infection in COVID-19 patients and its effect on mortality. Those who have severe clinical symptoms of the disease, and others requiring prolonged stay in intensive care units (ICU), are more susceptible to developing superinfections by nosocomial pathogens. Ventilator-acquired pneumonia (VAP) is the most common type of infection observed among COVID-19 patients, followed by bacteraemia with sepsis, and urinary tract infections (UTI). There is an urgent need for prospective studies to provide epidemiological, clinical, and microbiological data on superinfections, which can be used to form effective antimicrobial guidelines that could have an important role in disease outcomes. Full article

The present study examined the prevalence and correlates of psychosocial impairment in a large, national sample of Peruvian children and adolescents (ages 5.0–17.9) during the COVID-19 pandemic in late 2020. A sample of 8263 online questionnaires were completed by caregivers in Peru between 23 October–26 November 2020. In addition to sociodemographic and pandemic-related factors, the survey administered the Peruvian Spanish version of the Pediatric Symptom Checklist (PSC-17) to assess child psychosocial risk. The Patient Health Questionnaire (PHQ-9), Kessler-6 (K-6), and Brief Resilience Scale (BRS-6) assessed caregiver depression, psychological distress, and resilience, respectively. In this case, 33% of the children were at overall risk on the PSC-17. In adjusted models, caregiver distress, depression, and low resilience, as well as having a family member with a health risk factor were the strongest predictors of child psychosocial risk, accounting for nearly 1.2 to 2.1 times the likelihood of risk individually and 2.4 to 3.4 times the likelihood of risk when summed. Due to the opt-in sampling method, the obtained sample was likely skewed toward more advantaged families, suggesting that the study’s high prevalence of PSC-17 positivity might have been even higher in a more economically representative sample. Given the prevalence of psychosocial problems in Peruvian youth during COVID-19, preventive interventions, with a special focus on family-level approaches that involve and support parents as well as children, are clearly warranted. Full article

COVID-19 is a recent respiratory illness with high morbidity and mortality; therefore, the study and characterization of blood markers associated with the improvement or deterioration of COVID-19 patients are crucial. This study compared levels of interleukin 6 (IL-6), procalcitonin (PCT), D-dimer, cortisol, dehydroepiandrosterone sulfate (DHEA-S), c-reactive protein (CRP), 25-OH vitamin D, anti-SARS-CoV-2 IgG antibodies, and viremia in mild–moderate and severe–critical COVID-19 patients. In addition, the time course of blood markers was studied in severe–critical cases. The results show that levels of IL-6, PCT, D-dimer, and CRP, the cortisol/DHEA-S ratio, as well as positive viremia and anti-Spike IgGs were higher in severe–critical patients requiring hospitalization. During follow-up, most severe–critical cases displayed similar time patterns of IL-6 and viral load, whereas anti-SARS-CoV-2 antibody curves showed an inverse pattern. A decrease in IL-6 levels was associated with the improvement of COVID-19 patients, mostly through a reduced oxygen requirement. This preliminary study suggests that an increase in serum IL-6, PCT, D-dimer and CRP levels and the cortisol/DHEA-S ratio could support the selection of patients with poorer prognosis and the need for an intensive or alternative treatment. Additionally, changes in IL-6 during hospitalization were associated with changes in patient’s status mainly with a decrease in oxygen requirements, which indicates that serial measurements of IL-6 could predict the outcome of severe–critical patients with COVID-19 pneumonia. Full article

Objectives: Since 11 March 2020, when the World Health Organization declared the COVID-19 pandemic, trials have found that the pediatric population is the least affected, and most positive cases are asymptomatic or have mild symptoms such as fever and cough. Aims: The main objective of this study was to describe the percentage of positive tests among children who presented to the emergency department for symptoms compatible with SARS-CoV-2. Additional objectives were to identify clinical screening criteria to identify candidates to perform a polymerase chain reaction or antigen screening test. Patients/Methods: The study had a mixed cross-sectional and case-control design. Data were obtained from the electronic medical records of the emergency service of Hospital Sant Camil, Sant Pere de Ribes (Spain), from May 2020 to September 2021. Patients included had symptoms compatible with COVID-19 and a positive polymerase chain reaction or antigen SARS-CoV-2 screening test. Results: The study included 1508 patients with a mean age of 4.5 years (SD 4.2): 670 of whom were female (44.4%). The percentage of children with a positive polymerase chain reaction or antigen test was 3.51%. For the secondary objectives, some rules were created to create groups in which all patients tested negative: (1) Patients with abdominal pain, who did not present with diarrhea or fatigue, (2) Patients with asthma or allergies, (3) patients older than 3.5 years, with asthenia but without abdominal pain, and (4) patients younger than 3.5 years with abdominal pain and rash. Conclusions: The frequency of children who tested positive for COVID-19 was low among those with a clinical suspicion tested in the emergency room. Some combinations of symptoms and personal history were without exception associated with a negative polymerase chain reaction result for SARS-CoV-2 and could therefore help rule out the disease. Full article

Background and Objectives: New SARS-CoV-2 variants may impact the effectiveness of previously stored convalescent plasma (CCP). We defined levels of anti-delta and anti-omicron SARS-CoV-2 neutralizing antibodies (Nt-Abs) and investigated possible differences of past CCP Nt-Abs responses related to donor location in North and South Italy. Methods: Serum from 153 donors recovered from SARS-COV-2 infection (98 from northern and 55 from southern Italy) were analyzed for Nt-Abs characterization using our in house microneutralization assay. Results were compared to anti-Spike IgG measured by chemiluminescent assay (CLIA) to define a possible agreement with a more affordable test. Results: delta Nt-Abs titer in comparison to the reference strain (PV10734 D614G) showed a reduction of 82% in northern and 77% in southern Italy groups. Omicron Nt-Abs titer showed a reduction of 97%. CCP corresponding to Nt-Abs titer > 1:80 showed a median of 1365 BAU/mL for delta strain and 653 BAU/mL for reference strain. We found no statistical differences between Nt-Abs responses in North and South CCP donors. Conclusions: Not all past CCP could be used to treat patients with SARS-CoV-2 delta and omicron infections due to the lack of specific Nt-Abs. For the moment, the neutralization test remains the gold standard to select potential CCP donors. Interestingly, our study did not find NT-Abs differences between plasma collected from donors living in different areas of Italy. Full article

Coronavirus disease 2019 (COVID-19) has had devastating effects worldwide, with particularly high morbidity and mortality in outbreaks on residential care facilities. Amantadine, originally licensed as an antiviral agent for therapy and prophylaxis against influenza A virus, has beneficial effects on patients with Parkinson’s disease and is used for treatment of Parkinson’s disease, multiple sclerosis, acquired brain injury, and various other neurological disorders. Recent observational data suggest an inverse relationship between the use of amantadine and COVID-19. Adamantanes, including amantadine and rimantadine, are reported to have in vitro activity against severe acute respiratory syndrome coronavirus (SARS-CoV) and, more recently, SARS-CoV-2. We hypothesized that adamantanes have antiviral activity against SARS-CoV-2, including variant strains. To assess the activity of adamantanes against SARS-CoV-2, we used in vitro and in vivo models of infection. We established that amantadine, rimantadine, and tromantadine inhibit the growth of SARS-CoV-2 in vitro in cultured human epithelial cells. While neither rimantadine nor amantadine reduces lung viral titers in mice infected with mouse-adapted SARS-CoV-2, rimantadine significantly reduces viral titers in the lungs in golden Syrian hamsters infected with SARS-CoV-2. In summary, rimantadine has antiviral activity against SARS-CoV-2 in human alveolar epithelial cells and in the hamster model of SARS-CoV-2 lung infection. The evaluation of amantadine or rimantadine in human randomized controlled trials can definitively address applications for the treatment or prevention of COVID-19. Full article

The outbreak of COVID-19 presented many challenges to the global community. The scientific community developed vaccines to mitigate the virus spread and morbidity. Higher Education institutions shifted their research and development activities toward developing COVID-19 interventions. The University of Botswana set up a multi-disciplinary design team that responded to society’s COVID-19 needs. An agile methodology and co-creation process to design medical assistive devices was adopted for the study. These methods are human-centred, participatory, and have the added advantage of developing impactful, value-added, and acceptable products. This paper reports on the experiences of developing assistive breathing devices in response to the COVID-19 crisis. Experience gained from the study has enabled universities to continue to build local capacity in research and development to respond effectively and efficiently to future pandemics and any pressing societal challenge. Full article

Governments are seeking to slow the spread of COVID-19 by implementing measures that encourage, or mandate, changes in people’s behaviour such as the wearing of face masks. The success of these measures depends on the willingness of individuals to change their behaviour and their commitment and capacity to translate that intention into actions. Understanding and predicting both the willingness of individuals to change their behaviour and their enthusiasm to act on that willingness are needed to assess the likely effectiveness of these measures in slowing the spread of the virus. We analysed responses to two different regional surveys about people’s intentions and behaviour with respect to preventing the spread of COVID-19 in New Zealand. While motivations and intentions were largely similar across the regions, there were surprisingly large differences across the regions regarding the frequency of wearing face masks. These regional differences were not associated with regional differences in demographics (or in Alert levels) but were associated with regional differences in the number of confirmed cases of COVID-19. The results highlight the importance to policy design of distinguishing the factors that might influence the formation of behavioural intentions from those that might influence the implementation of those intentions. Full article